FDA accepts ApeX Therapeutics’ IND for clinical testing of APX3330 in pancreatic cancer
The US Food and Drug Administration (FDA) has accepted ApeX Therapeutics’ investigational new drug (IND) application for clinical testing of APX3330 in pancreatic cancer.
Click on this link for more information.
